SCHEMBL6928201

SCHEMBL6928201

OC1CCN(c2ccc(-c3nc(-c4ccccc4)c[nH]3)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 1/20 0.46
DGAT1 O75907 7/20 0.43
KCNH2 Q12809 5/20 0.43
PIM1 P11309 2/20 0.43
DYRK1A Q13627 2/20 0.43
CDC7 O00311 1/20 0.43
PLK4 O00444 1/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
PDPK1 O15530 1/20 0.43
JAK2 O60674 1/20 0.43
ROCK2 O75116 1/20 0.43
PAK4 O96013 1/20 0.43
CHEK2 O96017 1/20 0.43
EGFR P00533 1/20 0.43
NTRK1 P04629 1/20 0.43
PRKCG P05129 1/20 0.43
INSR P06213 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925668 0.87 CNR2 (0.53) ADKFYNKDM4EALDH1A1KMT2A
SCHEMBL6927559 0.86 RAD52 (0.44) DGAT1KCNH2DYRK1AL3MBTL1CNR2
SCHEMBL6925885 0.86 CNR2 (0.56) KDM4EALDH1A1GAAMAPTKMT2A
SCHEMBL6925410 0.86 HRH3 (0.45) DGAT1KCNH2FYNCNR2
SCHEMBL6924500 0.85 ATR (0.51) KCNH2CHEK1NTRK1MAPK1KDM4E
SCHEMBL6920372 0.85 CNR2 (0.50) ADKDGAT1KCNH2DYRK1ACNR2
SCHEMBL6925451 0.84 FYN (0.54) DGAT1KCNH2FYNMET
SCHEMBL6926900 0.84 CNR2 (0.53) ADKMAPK1ALDH1A1MAPTCNR2
SCHEMBL6925199 0.84 HRH3 (0.47) DGAT1FYNMAPK1KDM4EALDH1A1
SCHEMBL6920359 0.84 HRH3 (0.44) DGAT1KCNH2FYNCNR2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R ADK 2628/4885DGAT1 530/4885KCNH2 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.